1. Medtech Insight

Market Intel: Holding Out For Home Hemodialysis: Still-Modest Market Promises Bigger Growth

 
• By Jenny Blair

End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.

hemodialysis
The benefits of home hemodialysis is expected to drive the market for enabling technologies • Source: Shutterstock

According to the US Renal Data System's 2015 report, 468,000 patients in the country underwent dialysis in 2013. Globally Fresenius Medical Care AG & Co. KGAA , the largest dialysis service provider, estimates that there are currently three million patients with kidney failure that regularly undergo dialysis. And their numbers are expected to rise, driven in part by the increase of chronic diseases such as obesity and diabetes.

The cost of treating these patients is also substantial. In 2013, the Centers for Medicare and Medicaid Services (CMS) spent $30.9bn on these patients, accounting for 7.1% of total expenditures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 
• By Amanda Maxwell

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

Will NICE’s New Medtech Evaluation Plans Hit the Target for Patients and Industry?

 
• By Ashley Yeo

One year after the UK mooted the Rules-Based Pathway to give medtechs clarity on what can be expected from an evaluation, the devices industry says UK healthtech assessment and adoption processes are still failing to meet the needs of innovators and patients.

The Value Of Consumer Wearables Within The Clinic Is Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”